Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of TAR-200 with or without cetrelimab in BCG-unresponsive high-risk non-muscle invasive bladder cancer
NL-OMON54181Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine-releasing intravesical system and cetrelimab in non-muscle-invasive bladder cancer (NMIBC) and bladder cancer (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall complete response rate and Disease-free survival rate. Started Oct 2021; status: recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)bladder cancer
Beyond the preview
Go deeper on NL-OMON54181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54181.